Prescription of High-Dose Opioids Among People Living with HIV in British Columbia, Canada.

People living with HIV (PLHIV) often experience pain for which opioid medications may be prescribed. Thus, these individuals are particularly vulnerable to opioid-related harms, including overdose, misuse, and addiction, particularly when prescribed at high doses. We used a comprehensive linked popu...

Full description

Bibliographic Details
Published in:AIDS & Behavior Vol. 23; no. 12; pp. 3331 - 3340
Main Authors: Clark, Jessica, Fairbairn, Nadia, Nolan, Seonaid, Li, Tian, Wu, Anthony, Barrios, Rolando, Montaner, Julio, Ti, Lianping, the STOP HIV/AIDS in BC Study Group, Daly, Patty, Gustafson, Reka, Kendall, Perry R. W., Panessa, Ciro, Heath, Kate, Hogg, Robert S., Montaner, Julio S. G.
Format: research tables/charts Journal Article
Published: Springer Nature Dec2019
Online Access:View this record in EBSCOhost
Description
Summary:People living with HIV (PLHIV) often experience pain for which opioid medications may be prescribed. Thus, these individuals are particularly vulnerable to opioid-related harms, including overdose, misuse, and addiction, particularly when prescribed at high doses. We used a comprehensive linked population-level database of PLHIV in British Columbia (BC) to identify demographic and clinical characteristics associated with being prescribed any high-dose opioid analgesic, defined as > 90 daily morphine milligram equivalents (MME/day). Among PLHIV who were prescribed opioids between 1996 and 2015 (n = 10,780), 28.2% received prescriptions of > 90 MME/day at least once during the study period. Factors positively associated with being prescribed high-dose opioid analgesics included: co-prescription of benzodiazepines (adjusted odds ratio [AOR] = 1.14; 95% confidence interval 1.11–1.17); presence of an AIDS-defining illness (ADI; AOR = 1.78; 95% CI 1.57–2.02); seen by an HIV specialist (AOR = 1.24; 95% CI 1.20–1.29); substance use disorder (AOR = 1.46; 95% CI 1.25–1.71); and more recent calendar year (AOR = 1.05; 95% CI 1.04–1.06). Given the known risks associated with high-dose opioid prescribing, future research efforts should focus on the clinical indication and outcomes associated with these prescribing practices.